1Y Annualised Return
▲26.02%
3Y Annualised Return
▲49.24%
5Y Annualised Return
▲16.49%
Lupin SIP Return Calculator
Over the past
Total Investment of ₹65,00,000
Would have become ₹74,27,236 (+14.27%)
Daily SIP of ₹25,000 would have become ₹74,27,236 in 1 year with a gain of ₹9,27,236 (+14.27%)
Open
1,998.00
Prev. Close
2,023.20
Total Traded Value
95.16 Cr
Market Cap (in crs)
91,320.83
Face Value
2
Turnover (in lacs)
9,516.10
Lupin Key Financials
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
Lupin Quarterly Revenue
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
5667.13 Cr | 5767.71 Cr | 5672.73 Cr | 5600.33 Cr | 4960.79 Cr |
Lupin Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
22903.72 Cr | 20130.99 Cr | 16715.02 Cr | 16547.17 Cr | 15299.25 Cr | 15858.52 Cr |
Lupin Quarterly Net Profit/Loss
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
782.38 Cr | 858.86 Cr | 859.48 Cr | 805.54 Cr | 368.22 Cr |
Lupin Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
3306.26 Cr | 1935.57 Cr | 447.69 Cr | -1509.72 Cr | 1226.6 Cr | -403.82 Cr |
Result Summary
-
Lupin Ltd reported a 14.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.7%.
-
Its expenses for the quarter were down by 5.4% QoQ and up 6.7% YoY.
-
The net profit decreased 57.1% QoQ and increased 51.9% YoY.
-
The earnings per share (EPS) of Lupin Ltd stood at 7.9 during Q4FY25.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Lupin Technical Analysis
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 263699 Rs | 484689 Rs |
Week Rs | 591094 Rs | 978571 Rs |
Month Rs | 650258 Rs | 1120502 Rs |
Similar stocks
Similar Stocks
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | 66,969.38 | 25325 | 32200 | 31,575.00 | -0.36% | 3.70% | 10.00% | 14.12% | 76.01% | 1.51% | 47.39 | 42.57 | 15.84 | |
- | 67,394.66 | 1010 | 1592 | 1,155.20 | -0.94% | -6.01% | -4.82% | -8.33% | 122.56% | 0.00% | 38.60 | 42.57 | 3.28 | |
- | 98,102.78 | 795 | 1324.3 | 978.80 | 1.54% | 8.11% | -0.36% | -10.60% | 177.17% | 1.13% | 16.99 | 42.57 | 4.63 | |
- | 1,10,074.44 | 2755.9 | 3590.7 | 3,258.80 | 3.11% | 0.51% | -2.79% | 13.13% | 129.52% | 0.98% | 57.74 | 42.57 | 14.49 | |
- | 57,959.13 | 4491.65 | 6439.9 | 4,846.50 | -0.31% | -5.44% | -9.77% | -4.76% | 56.65% | 0.93% | 27.74 | 42.57 | 4.70 | |
- | 98,269.35 | 1901.05 | 3054.8 | 2,390.00 | 1.23% | -6.52% | -9.86% | 6.30% | 0.00% | 0.00% | 52.17 | 42.57 | 6.71 |
Lupin Company background
Lupin Ltd
Lupin Limited is a top pharmaceutical company in India, globally recognized for its research and innovation orientation. It was established in 1968 by Dr. Desh Bandhu Gupta with a humble vision, which was to provide medicines at affordable prices to all and fulfill medical requirements that were not fulfilled. Lupin has become a worldwide giant over the years, manufacturing a broad array of drugs such as branded and generic medicines, biotechnology items, and essential ingredients used in the production of other drugs.
A Global Pharmaceutical Powerhouse
Lupin’s journey from a domestic-focused company to an internationally recognized pharmaceutical leader shows its relentless pursuit of excellence. The company operates in over 100 countries across North America, Europe, Asia-Pacific, and Africa. It’s headquartered in Mumbai, India. It has quite a strong presence in developed markets such as the United States, where it is among the top five generic pharmaceutical companies by prescriptions. Additionally, Lupin is a prominent player in emerging markets, catering to the healthcare needs of millions with high-quality and affordable medications.
Research & Development: The Core of Lupin’s Success
Innovation has been one of the most important cornerstones of Lupin's growth strategy. The company has invested significantly in research and development (R&D), establishing many state-of-the-art facilities across the world. These R&D centers focus greatly on creating complex generics, biosimilars, and specialty products, demonstrating Lupin’s commitment to advancing healthcare solutions. Lupin’s prowess in R&D has led to a robust pipeline of products that address quite a few therapeutic areas, including cardiovascular diseases, respiratory ailments, central nervous system disorders, diabetes, and oncology.
Therapeutic Expertise
Lupin's wide-ranging product portfolio covers a fairly substantial number of therapeutic areas. It holds a leadership position in anti-tuberculosis treatments, reflecting its dedication to combating global health challenges. Also, the company has made great strides in therapies for cardiovascular health, diabetes management, respiratory conditions, and women’s health. Lupin has managed to solidify its reputation as a trusted partner in the pharmaceutical industry by aligning its products with the needs of not only patients but also healthcare providers.
Manufacturing Excellence
Lupin's production facilities are among the strongest forces behind its success. The organization has numerous top-notch production facilities approved by top regulatory bodies like the US FDA, UK MHRA, and WHO. All these facilities have a fair number of state-of-the-art technologies to produce medicines of high quality. Lupin's focus on upholding high-quality standards reflects its commitment towards providing safe and effective pharmaceutical drugs to markets all around the world.
Strategic Acquisitions and Partnerships
Lupin has strategically expanded its reach and capabilities through acquisitions and partnerships. The acquisition of Gavis Pharmaceuticals and Novel Laboratories in the United States marked a great milestone in strengthening Lupin’s position in the world’s largest pharmaceutical market. The company’s partnerships with global pharmaceutical leaders have also enabled it to enhance its product offerings and cater to unmet medical needs.
Commitment to Sustainability
Other than its business activities, Lupin is greatly dedicated to corporate social responsibility and sustainable practices. Also, the firm is actively engaged in minimizing its environmental impact through green initiatives and optimal use of resources. Lupin's philanthropic organization, the Lupin Human Welfare and Research Foundation (LHWRF), has played a great role in empowering underprivileged society by focusing on healthcare, education, and skill development initiatives.
Financial Performance and Market Presence
Lupin has consistently delivered robust financial performance, driven by its diversified product portfolio, geographic expansion, and operational efficiency. The company’s ability to adapt to evolving market dynamics has also allowed it to maintain quite a competitive edge in the global pharmaceutical space. Investors often monitor Lupin share price as a barometer of the company’s market strength as well as its future prospects.
Brief Overview
While Lupin continues on its growth and innovation journey, it is always extremely committed to tackling new healthcare issues that emerge. The company is actively exploring new therapeutic areas, leveraging digital technologies, and enhancing its R&D capabilities to deliver breakthrough solutions. By staying true to its founding principles and embracing a forward-looking approach, Lupin aims to create a lasting impact on global healthcare.
Lupin Limited’s story is one of resilience, innovation, and commitment to improving lives. From its humble beginnings to becoming a global pharmaceutical powerhouse, Lupin has consistently demonstrated its ability to adapt and thrive in a dynamic industry. With its unwavering focus on quality, sustainability, and patient-centric solutions, Lupin is well-positioned to lead the future of healthcare innovation.
As of 13 Jun, 2025, LUPIN share price is ₹1999.6. The stock opened at ₹1998 and had closed at ₹2023.2 the previous day. During today’s trading session, LUPIN share price moved between ₹1,980.00 and ₹2,019.00, with an average price for the day of ₹1.50. Over the last 52 weeks, the stock has recorded a low of ₹1,543.00 and a high of ₹2,402.90. In terms of performance, LUPIN share price has declined by 3.7% over the past six months and has increased by 26.02% over the last year.
Lupin FAQs
What is Share Price of Lupin ?
Lupin share price is ₹2001.5 in NSE and ₹2004.85 in BSE as on 13/6/2025.
How has Lupin shares performed in the past ?
Lupin share price in the past 1-year return was 24.55. The Lupin share hit a 1-year low of Rs. 1543 and a 1-year high of Rs. 2402.9.
What is the market cap of Lupin ?
The market cap of Lupin is Rs. 91320.83 Cr. as of 13/6/2025.
What is the current P/E ratio of Lupin ?
The PE ratios of Lupin is 22.63 as of 13/6/2025.
What is the current PB ratio of Lupin ?
The PB ratios of Lupin is 3.76 as of 13/6/2025
What is the Mutual Fund shareholding in Lupin ?
The Mutual Fund Shareholding in Lupin was 17.55% at the end of 13/6/2025.
How to buy Lupin shares?
You can easily buy Lupin shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
Please be aware that Lupin stock prices are subject to continuous fluctuations due to various factors.